Conexeu Completes 12-Month Tissue Restoration Study, Targets Q1 2027 510(k) Filing
CNXU•Conexeu Sciences completed its 12-month P.R.O.O.F preclinical study, demonstrating tissue restoration in both small-volume facial and 200cc-equivalent large-volume models and meeting injectability and volumizing benchmarks. The company plans a predicate-based 510(k) wound-care submission in Q1 2027 as its first regulatory step toward entering the $11 billion medical aesthetics market.
1. Milestone Completion
Conexeu Sciences has finalized the P.R.O.O.F (Performance and Regeneration Outcomes of Flowable Collagen) phase, a 12-month preclinical program providing the core evidence base for its CXU™ tissue-restoration platform. This completion marks a key catalyst in advancing toward medical aesthetics applications.
2. Study Results
The P.R.O.O.F study met all objectives, demonstrating tissue restoration in a cheek model and in a 200cc-equivalent large-volume model. CXU™ also cleared injectability through a fine-gauge needle and volumizing performance benchmarks, with full results slated for peer-reviewed publication.
3. Regulatory Pathway and Market Opportunity
Conexeu plans a predicate-based 510(k) wound-care submission in Q1 2027 targeting a 90-day FDA review as a faster regulatory entry point. With the GLP-1 weight-loss market set to reach $190 billion by 2035, the tissue-restoration gap is projected to grow from $0.7 billion to $2.0 billion by 2030, underpinning the CXU™ market opportunity and backed by patents in over 40 jurisdictions.
